ArticleLaryngoscope investigative otolaryngology2026
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization.Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We evaluated the impact of teprotumumab therapy (TT) introduction on orbital decompression (OD) utilization for thyroid eye disease (TED) and compared rates of significant exophthalmos reduction (SER) and diplopia between TT and OD. Methods: Newly diagnosed TED patients treated pre (2015-2020) and post teprotumumab (2020-2025) FDA approval were identified from the EHR. Utilization trends, diplopia rates, and immediate (≤ 6 weeks post-intervention) and long-term follow-up SER (≥ 2 mm reduction) were studied. Results: Of 406 TED patients, 53 (36.8%) underwent OD in the pre-TT cohort ( Conclusions: Rates of OD surgery declined following FDA approval of teprotumumab. OD achieved sustained and greater exophthalmos reduction but carried a higher risk of diplopia. Contemporaneous OD indications may have evolved to use in TT-recalcitrant TED or those in need of urgent decompression. Level of Evidence: 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.